当前位置:循环首页>正文

[CIT2011]2011年再灌注研究:贯彻针对绝大多数患者的最佳策略——Harry Suryapranata教授访谈

Reperfusion in 2011: Implementing the Best Strategy for the Greatest Number of Patients——Dr. Harry Suryapranata Interview

作者:  HarrySuryapranata   日期:2011/3/25 14:00:26

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

If you talk about reperfusion therapy I think it is necessary to go back to what it was that caused it. One of the latest breakthroughs in interventional cardiology was back in 1993 when the treatment of acute myocardial infarction (MI) patients changed away from medical therapy.

  International Circulation:  Thank you Dr. Suryapranata for joining us today.  I’d like to ask you a few questions today about treating STEMI patients, but first address you talk today speaking about the best reperfusion strategy for the greatest number of patients, a slight different viewpoint from the more often discussed individualized treatment.  Can you briefly define some of the characteristics of the “greatest number of patients” as you discussed in your presentation?
  Dr. Harry Suryapranata:  If you talk about reperfusion therapy I think it is necessary to go back to what it was that caused it.  One of the latest breakthroughs in interventional cardiology was back in 1993 when the treatment of acute myocardial infarction (MI) patients changed away from medical therapy.  If you look at the mortality rate, lets say in my country, the Netherlands, which is a small country of 60 million inhabitants, in the 1950s the mortality rate was approximately 25%.  It later went down dramatically to less than 10%, particularly after the introduction of thrombolytic therapy, one of the reperfusion therapies, and subsequently primary PCI, which is what we are talking about today.  It took 10 years after that was first published before these treatments were recommended in guidelines.  The problem now is not how to do it.  PCI, or coronary intervention, for acute MI can be done by everyone who is skillful in conducting PCI.  The key point is organization.  How do we bring the greatest number of those patients early enough to undergo that treatment and achieve these positive outcomes.  The key point is organization.
  There have been three key achievements since the breakthrough in 1993.  One is the development of PCI techniques over the past decades.  Second is the adjunctive drug therapy.  There is currently drug therapy available to us such as an extensive anti-thrombotic arsenal to treat before and after the coronary intervention.  Finally, the better organization of CATH which has resulted in an improvement in assessment to PCI centers.

[1]  [2]  [3]  下一页

版面编辑:赵书芳  责任编辑:聂会珍



再灌注Harry Suryapranata急性心肌梗死MISTEMI

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530